Online Medication Management: What the Evidence Says About Telehealth Psychiatric Care
Why Patients and Providers Are Turning to Telehealth for Psychiatric Care
Psychiatric medication management requires regular follow-up visits, lab monitoring, and ongoing communication between patients and clinicians. For many patients, logistical barriers — including transportation, work schedules, and caregiving responsibilities — can interfere with consistent attendance. Telehealth has emerged as an evidence-supported option for delivering psychiatric care remotely, and its use has expanded substantially in recent years. A 2026 study in JAMA Psychiatry found that nearly half of U.S. adult mental health outpatients in 2021–2022 received one or more telemental health visits.
Telehealth psychiatric visits are not a replacement for professional evaluation and diagnosis. All psychiatric medication management — whether conducted in person or via telehealth — should be overseen by a licensed, board-certified clinician who can assess symptoms, order appropriate tests, and make individualized treatment decisions.
What the Research Shows About Telehealth vs. In-Person Psychiatric Care
Multiple meta-analyses and systematic reviews have compared telepsychiatry with in-person care across a range of psychiatric conditions. A 2023 meta-analysis of 32 randomized controlled trials (3,592 participants across 11 psychiatric diagnoses) found no significant difference in symptom improvement between telepsychiatry and face-to-face treatment when all diagnoses were combined. The same analysis found no significant difference in all-cause treatment discontinuation between the two modalities.
A separate meta-analysis of 57 studies found that videoconference-based mental health services produced treatment effects largely equivalent to in-person care across 281 individual outcomes and over 4,300 patients. A review of 22 RCTs similarly concluded that telehealth platforms generally produce comparable outcomes to face-to-face care for conditions including depression, PTSD, and mixed diagnoses. The majority of these studies also found no significant differences in patient satisfaction, therapeutic alliance, or treatment discontinuation.
For depression specifically, a systematic review of nine RCTs (1,268 patients) found no differences in depression severity between telehealth and face-to-face care at post-treatment. A large observational study of over 3,400 patients at outpatient psychiatric clinics found that the transition to telehealth was associated with fewer missed appointments and reduced depressive symptoms.
These findings support telehealth as a viable modality for ongoing psychiatric medication management when conducted by a qualified clinician. However, evidence gaps remain for certain populations, including patients with psychotic disorders and children/adolescents, and efficacy may vary by diagnosis.
How Telehealth Medication Management Visits Work
During a telehealth medication management visit, a clinician conducts a structured clinical assessment via secure videoconference. This typically includes:
- Reviewing current psychiatric symptoms (mood, anxiety, sleep, concentration, energy)
- Assessing medication efficacy and tolerability, including side effects
- Discussing treatment goals and functional outcomes
- Coordinating with other aspects of care, such as psychotherapy, lifestyle modifications, or referrals
The American Psychiatric Association's best practices guidelines for telemental health emphasize that patients should be in a private setting, use a device with a camera, and have a stable internet connection. Clinicians are expected to maintain the same standard of care as in-person visits, including thorough documentation and clinical assessment.
Telehealth visits are not appropriate for self-diagnosis or self-directed medication changes. All medication adjustments should be made by the prescribing clinician based on a comprehensive clinical evaluation.
Laboratory Monitoring Remains Essential
Many psychiatric medications require periodic laboratory monitoring regardless of whether visits occur in person or via telehealth. Clinical guidelines recommend the following monitoring for commonly prescribed psychiatric medications:
- Lithium: Serum lithium levels, renal function, thyroid function (TSH), and calcium levels should be monitored regularly — typically every 3 to 6 months once a stable dose is achieved.
- Valproate (divalproex): Liver function tests, complete blood counts, and serum drug levels should be checked periodically. Valproate is a known teratogen and is not recommended for women of childbearing age without careful risk-benefit discussion.
- Atypical antipsychotics: Weight, BMI, fasting glucose, hemoglobin A1c, and fasting lipid panels should be measured at baseline, at 3 months, and at least annually thereafter, given the risk of metabolic syndrome.
- Carbamazepine: Liver enzyme levels require regular monitoring due to the risk of hepatotoxicity.
- Stimulants (for ADHD): Monitoring for appetite suppression, insomnia, blood pressure, heart rate, and growth trajectory (in children) is recommended, with more frequent visits early in treatment.
In a telehealth model, clinicians order labs electronically, and patients complete bloodwork at a local laboratory. Results are transmitted securely to the prescribing clinician for review. Telehealth does not eliminate the need for laboratory monitoring — it simply changes the logistics of how lab orders are placed and results are communicated.
Follow-Up Visit Frequency: What Guidelines Recommend
The frequency of follow-up visits in psychiatric medication management is guided by clinical phase and individual patient factors:
- Starting a new medication or adjusting a dose: A JAMA review recommends initial contact at 2 weeks, with subsequent visits every 4 to 6 weeks until remission or satisfactory response. The VA/DoD clinical practice guideline for major depressive disorder recommends monitoring at least monthly after initiation or a change in treatment until remission is achieved.
- Maintenance phase: Once symptoms are stable, the AACAP practice parameter notes that patients with a stable, high-quality response can be seen as infrequently as two to four times per year. Follow-up visits during maintenance should continue to assess symptoms, medication adherence, and side effects.
- Discontinuation phase: More frequent monitoring may be needed when tapering medications, to detect withdrawal symptoms or early signs of relapse.
Telehealth can facilitate adherence to these recommended follow-up intervals by reducing logistical barriers to attendance. For many patients, follow-up by telephone or online messaging may substitute for some in-person visits.
When In-Person Care May Be More Appropriate
Telehealth is not suitable for all clinical situations. The American Psychiatric Association's telemental health guidelines state that the appropriateness of telehealth for any individual patient is at the discretion of the provider and should be based on an individualized assessment. Factors that may favor in-person evaluation include:
- Active suicidal ideation or self-harm risk: Most guidelines advise particular caution with telehealth for patients who are actively suicidal, violent, or homicidal, as assessing and managing emergent safety concerns remotely can be challenging.
- Severe or unstable psychiatric symptoms: Some evidence suggests that patients with higher symptom severity may have worse outcomes with telehealth compared to in-person care.
- Need for physical or neurological examination: Certain clinical assessments — such as evaluating extrapyramidal symptoms from antipsychotics or conducting a detailed neurological exam — require in-person evaluation.
- Substance use crises: One meta-analysis found higher treatment discontinuation rates with telepsychiatry for substance misuse compared to in-person care.
- Cognitive or technological limitations: Patients must be able to set up and use the videoconferencing system and maintain a private, cooperative treatment environment.
A hybrid model — combining telehealth and in-person visits — may be appropriate for many patients and allows clinicians to tailor the care modality to the patient's current clinical needs.
The Importance of Professional Evaluation
Psychiatric conditions such as depression, anxiety, ADHD, and bipolar disorder require professional diagnosis and ongoing clinical management. Symptoms of these conditions can overlap with medical illnesses, substance use, and other psychiatric disorders. Self-diagnosis based on online information is unreliable and may lead to inappropriate treatment or missed diagnoses.
Similarly, psychiatric medications carry risks including drug interactions, metabolic effects, cardiac effects, and teratogenicity. These medications should only be prescribed, adjusted, or discontinued under the supervision of a qualified clinician who can weigh the risks and benefits for each individual patient.
If symptoms of a mental health condition are present, the appropriate next step is to seek evaluation from a licensed mental health professional — whether in person or through a legitimate telehealth platform staffed by board-certified clinicians.
Take The Next Step Toward Calmer, More Confident Care
If you are ready for more consistent, personalized support with your medications, we are here to help. Our online medication management services make it easier to stay on track and adjust your treatment as your needs change. At Santana Mental Health Services, we work with you to understand what is and is not working, so your plan feels manageable and effective. Have questions or want to schedule an appointment? Simply contact us to get started.
